Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Apr 19, 2015 2:48pm

134 Views

Post# 23644661

RE:A layman tries to explain RVX and p53

tundup, what can I say but THANKS for the insightful post!!

I realize that RVX is exploring rvx-208 at the molecular level with microarray analysis and gaining better understanding of the biochemical pathways using the Emerald Logic FACET Predictive modelling.

However, I did not see the p53 information and you are right. The rvx-208 impact is truly extraordinary because it demonstrates the multi-faceted set of epigenetic pathways that rvx-208 evokes and hence the multiple potential health benefits.

I sense there are many scientists starting to focus in on this area.

I appreciate your insights and sound critical thinking.
Best regards
Toinv

Bullboard Posts

Rich TV Live's Stocks to Watch this week (May 31, 2024)